Abstract
Chronic spontaneous urticaria (CSU) is a debilitating condition that can substantially affect patients' quality of life (QoL), mental health and ability to perform daily tasks. International guidelines on the management of CSU, jointly developed by the European Academy of Allergy and Clinical Immunology (EAACI), Global Allergy and Asthma European Network (GA2LEN), European Dermatology Forum (EDF) and World Allergy Organization (WAO), recommend a treat-to-target strategy until symptom control or remission is achieved. This may mean stepping up or down in the treatment algorithm according to the course of CSU and re-evaluating the need for continued/alternative drug treatment. Utilising patient-reported outcome (PRO) tools in daily clinical practice will create a gold standard for care in CSU, aiding the treat-to-target strategy, increasing patient wellbeing and reducing healthcare costs through optimal treatment and management of patients with CSU. This article outlines PRO tools recommended by EAACI/GA2LEN/EDF/WAO guidelines for assessment of CSU symptom control, severity and QoL.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
